Finance

Lists
Why is INBX up 2,43%?
Dive Deeper
INBX:NASDAQ
Inhibrx Biosciences Inc
95,01 USD
+2,43%
(+2,25) 1D
9-окт., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for INBX...
Open
92,70 USD
High
95,81 USD
Low
92,70 USD
Mkt. cap
1,40 млд
Avg. vol.
319,90 миң
Volume
86,82 миң
52-wk high
155,29 USD
52-wk low
28,16 USD
EPS
-8,88 USD
Shares outstanding
14,72 млн
No. of employees
110
Open
92,70 USD
High
95,81 USD
Low
92,70 USD
Mkt. cap
1,40 млд
Avg. vol.
319,90 миң
Volume
86,82 миң
52-wk high
155,29 USD
52-wk low
28,16 USD
EPS
-8,88 USD
Shares outstanding
14,72 млн
No. of employees
110
News stories
From web sources and news partners
About Inhibrx Biosciences Inc
CEO-
Employees110
Founded2024
HeadquartersЛа Джолла, Калифорния, Америка Кошмо Штаттары
Sector-
Websiteinhibrx.com
Analyst ratings
Based on 3 analysts giving stock ratings to INBX in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for INBX in the last 3 months.
Highest
Current 95,01 USD
325,00 USD (+242,07%)
Average
266,67 USD (+180,68%)
Lowest
230,00 USD (+142,08%)
Analyst
Recommendation
Action
Price target
Projected
Date
Robert Burns
H.C. Wainwright
Buy
Reiterated
245,00 USD
+157,9%
09/09/2026
Oliver McCammon
LifeSci Capital
Buy
Maintained
230,00 USD
+142,1%
09/08/2026
Dara Azar
Stifel Nicolaus
Buy
Maintained
325,00 USD
+242,1%
08/21/2026
Unknown Analyst
Stifel Nicolaus
Buy
Initiated
150,00 USD
+57,9%
04/08/2026
Last report
2026-ж., 13-авг.
Fiscal period
Q2 2026
-2,34 USD / -2,28 USD
-2,63%miss
Revenue / Est. (USD)
- / 0,00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
-
-
-
-
Cost of goods sold
28,54 млн
25,35 млн
25,22 млн
23,90 млн
Cost of revenue
28,54 млн
25,35 млн
25,22 млн
23,90 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5,28 млн
5,57 млн
5,71 млн
8,25 млн
Operating expense
5,28 млн
5,57 млн
5,71 млн
8,25 млн
Total operating expenses
33,81 млн
30,92 млн
30,93 млн
32,15 млн
Operating income
-33,81 млн
-30,92 млн
-30,93 млн
-32,15 млн
Other non operating income
-46,00 миң
-39,00 миң
-12,00 миң
-68,00 миң
EBT including unusual items
-35,26 млн
-32,83 млн
-33,44 млн
-36,65 млн
EBT excluding unusual items
-35,26 млн
-32,83 млн
-33,44 млн
-36,65 млн
Income tax expense
-
-
-
3,00 миң
Effective tax rate
-
-
-
-0,01%
Other operating expenses
-
-
-
-
Net income
-35,26 млн
-32,83 млн
-33,44 млн
-36,65 млн
Net profit margin
-
-
-
-
Earnings per share
-2,28
-2,11
-2,15
-2,34
Interest and investment income
1,78 млн
1,31 млн
1,01 млн
1,26 млн
Interest expense
-3,18 млн
-3,18 млн
-3,51 млн
-5,69 млн
Net interest expenses
-1,40 млн
-1,87 млн
-2,50 млн
-4,43 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-33,23 млн
-30,36 млн
-30,39 млн
-31,63 млн
Gain or loss from assets sale
3,00 миң
9,00 миң
-
14,00 миң
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору